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Abstract To assess the correlation between quality of life
(QoL) and satisfaction with life (SL) in SLE patients and
correlate both with clinical symptoms of the disease. The
study was performed in 83 patients. QoL was assessed by
Short Form 36, and SL was assessed by the Satisfaction
with Life Scale. Clinical manifestations presented at the
time of examination were taken into consideration. SLE
patients assessed their QoL and SL as rather low. Those
with photosensitivity as well as neurological symptoms
presented lower QoL in particular domains, while those
with renal manifestation of SLE assessed their QoL as
higher. Similar observations were made for SL only in
relation to neurological symptoms. Moreover, our findings
show that although SL is a part of QoL, both these
parameters should be distinguished in order to fully assess
the state of the patient.
Keywords Quality of life.Satisfaction with life.SF-36.
SWLS.SLE.Clinical manifestations
Introduction
The term quality of life (QoL) was introduced in the 1970s.
Originally, it was restricted to living in particular circum-
stances, and therefore had an economic value. Later, it was
extended to the concept of health and disease. Finally, in
the 1990s, Schipper [1–3] proposed the notion of health-
related quality of life (HRQoL). This expression is
narrower than QoL because HRQoL only focuses on the
influence of health and disease [4, 5]. It is often used for
chronic and incurable diseases, without taking other
nonmedical aspects into account.
While assessing QoL, the satisfaction with life (SL) is
also considered. The term SL is very similar to quality of
life, nevertheless the terms should be distinguished; QoL is
affected by more aspects than SL and includes other issues
such as age, sex, education, occupation, social functioning,
and of course, health, whereas satisfaction with life can be
understood as contentment, and is a part of the subjective
well-being connected with happiness and positive emotions
[6]. Furthermore, satisfaction with life is defined as a
difference between one’s own assumptions and plans, and
real achievements [7]. However for some researchers, the
two terms are indistinguishable. Our aim, therefore, was not
to distinguish those two terms, but to compare them or
discover whether the influence of a disease’s clinical
symptoms, and of other factors connected with its course,
has a significant effect on QoL and SL.
Systemic lupus erythematosus (SLE) is a chronic disease
of the connective tissues, which can wax and wane [8]. It
occurs ten times more frequently in women, more so in
young ones. Because of the vast diversity of clinical
manifestations and damage to organs which occur in the
course of the disease, the predictions are uncertain.
To fully assess the state of patients, especially those with
chronic and incurable diseases such as SLE, quality of life
is frequently taken into consideration [9] and a QoL
assessment is performed to recognize and understand any
determining factors. The next step is an attempt to improve
QoL. To our knowledge, even though there are numerous
publications concerning quality of life and systemic lupus
erythematosus, the influence of clinical symptoms on
patients’ QoL is not studied enough. Moreover, there is a
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Aim
The main aim of this paper is to assess quality of life,
together with satisfaction with life, in systemic lupus
erythematosus patients. Moreover, we will attempt to
answer the question whether the patients who assess their
own QoL as high will also evaluate their SL in the same
way. Any correlations between those parameters and
clinical manifestation of the disease, activity of the disease,
and damage index will also be noted.
Materials and methods
The study was performed on 83 patients (78 women and
five men) under the care of the Department of Dermatology
and Venereology, Medical University of Lodz as well as its
Outpatient Clinic. The average duration of the disease was
about 8.9 years. SLE activity was assessed using Systemic
Lupus Activity Measure (SLAM) [10]. The disease was
assumed to be active when the patient scored 7 or more
points [11]. The degree of damage which could occur
during the course of SLE was determined on the basis of
the Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index [12].
Most of the patients (59%) achieved 7 or more points in
SLAM, indicating that SLE symptoms were clinically
important [11]. Nevertheless, they presented a low-
damage index. Among the most often observed clinical
manifestations of SLE, are: malar rush, photosensitivity,
arthralgia, and laboratory abnormalities (anemia, leucope-
nia, or thrombocytopenia). Clinical characteristics of the
patients are presented in Table 1.
The quality-of-life measurement was made using the
Short Form 36 Health Survey (SF-36) [13]. This is a
standard questionnaire that allows quality of life to be
assessed, both in the general healthy population as well as
groups of sick people. It consists of 36 questions grouped
into 8 domains measuring different aspects of QoL (Physical
Functioning (PF), Role Physical (RP), Bodily Pain (BP),
General Health (GH), Vitality (VT), Social Functioning (SF),
Role Emotional (RE), Mental Health (MH)). Obtained results
are converted into a scale from 0 to 100, where 0 means the
lowest quality of life and 100 means the highest one, which
makes it possible to interpret data and draw conclusions
about the patients’ quality of life without using norms (which
do not exist for Polish population) or a control group.
The Satisfaction with Life Scale was used to measure the
patients’ satisfaction with life [14]. It evaluates satisfaction
with life without taking into consideration the somatic
symptoms of the disease, and is suitable for people at any
age. The questionnaire consists of five statements to which
the patient assigns a value from 1 to 7, depending on how
much the respondent agrees with it. It is possible to get a total
score between 5 to 35 points. The scores are then converted
into stens from 0 to 10. A sten is a unit of a psychological test
which is normalized so that the mean value of the population
is 5.5, and the standard deviation is 2. According to the
Polish norms, a result from 1 to 4 stens reflects low
satisfaction with life, 5 and 6 medium, and from 7 to 10 high.
The study was approved by the Bioethics Committee of
the Medical University of Lodz, Poland (Number RNN/
124/06/KE). The patients were informed about the aim of
Table 1 Characteristics of the patients
Parameter Value
Number of patients 83
Women/men 78/5
Mean age (range) 42.7 (21–71) years
Mean duration of the disease 8.9 years
Activity of the disease (SLAM) 4-23 (x=12.31)
Patients in an inactive stage of SLE 34 (41%)
Patients in an active stage of SLE 49 (59%)
Clinical manifestations
Malar rush 43 (52%)
Discoid rash 6 (7%)
Photosensitivity 64 (77%)
Oral ulcers 6 (7%)
Arthralgia 73 (88%)
Serositis 5 (6%)
Renal disorder 18 (22%)
Neurologic disorder 10 (12%)
Hematologic disorder 55 (66%)
Immunologic disorder (anti-dsDNA, anti-Sm) 13 (16%)
SLICC/ACR DI
Patients who obtained 0 point 50 (60.24%)
Patients who obtained >1 point 33 (39.76%)
Damage index—medium; SD x=0.67; SD=1.11
Damages:
Ocular 6 (18.18%)
Neuropsychiatric 10 (30.3%)
Renal 5 (15.15%)
Pulmonary 0
Cardiovascular 7 (21.21%)
Peripheral vascular 7 (21.21%)
Gastrointestinal 1 (3.03%)
Mucoskeletal 4 (12.12%)
Skin 3 (9.1%)
Other 0
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Statistical analysis
All results were presented as numeral values from mini-
mum (Min) to maximum (Max), also the arithmetical mean
(x), median (Me), and standard deviation (SD) were given.
Mean results were compared by the Mann–Whitney U and
the Kruskal–Wallis tests. Correlations between the obtained
results were assessed using the Spearman’s rank correlation
coefficient (ρ). Differences at p<0.05 were considered
statistically significant.
Results
Quality of life and satisfaction with life
The obtained data revealed that the patients with systemic
lupus erythematosus presented rather low scores in both
quality of life as well as satisfaction with life; they did not
achieve mean values of 60 in any QoL domain (Fig. 1).
Particularly low results were observed in two domains: RP
(x=8.66, SD=11.83) and RE (x=11.55, SD=10.64), while
other parameters that assessed psychological and somatic
functioning were also low, but still relatively higher
(Fig. 2). The patients obtained the highest results in three
domains: PF (x=55.36, SD=26.64), SF (x=56.48, SD=
27.49), and MH (x=51.76, SD=17.64). Most of the patients
(62%) assessed their satisfaction with life as low (0–4
stens), 17% of the patients assessed it as medium (5–6
stens), and 21% as high (7–10 stens).
In the range of low values, the patients gave answers that
were close to the medium results. A similar situation was
observed for medium values, but not for high ones. Here,
the answers were close to the lower border (Fig. 3).
Looking for correlations between quality of life and
satisfaction with life, statistically significant positive corre-
lations were observed for all SF-36 domains (Table 2).
Quality of life and clinical manifestations of SLE
The patients presented a vast diversity of clinical symptoms
for SLE. The most common manifestations were arthralgia,
myalgia, photosensitivity, malar rush, and hematological
abnormalities (Table 1). Statistically significant negative
correlations were observed between photosensitivity and
RE (p=0.04) as well as between neurological symptoms of
SLE and SF (p=0.04) (Fig. 3). For renal manifestations of
the disease and MH, the observed correlations were also
statistically significant but positive (p=0.04) (Fig. 3). There
were no statistically significant correlations between other
clinical symptoms of SLE and quality of life (p>0.05).
Satisfaction with life and clinical manifestations of SLE
A statistically significant negative correlation between
neurological symptoms and SL was present (p=0.04).
Correlations for other manifestations were statistically
insignificant (p>0.05).
Quality of life, satisfaction with life, and activity
of the disease
Statistically significant negative correlations were found
only between the activity of SLE and PF, MH and VT
Fig. 1 Quality of life in SLE
patients using SF-36
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statistical significance. There were no statistically signifi-
cant correlations between the activity of the disease and
other domains of SF-36 (Table 3).
In the investigated group of the patients, a negative but
statistically insignificant correlation was present between
the satisfaction with life and the activity of the disease
(p>0.05).
The results obtained by the SLE patients in an active and
inactive state are presented in Table 4.
Quality of life, satisfaction with life, and damage index
Statistically significant negative correlations were present
only between the damage index and RP as well as VT
(Table 5). There were no statistically significant correlations
between the damage index, the satisfaction with life and the
activity of SLE (p>0.05).
Discussion
Our results reveal that systemic lupus erythematosus, as a
chronic and incurable disease, has a great influence on the
patients’ quality of life as well as their satisfaction with life.
Moreover, differences between the presented results of QoL
and SL suggest that those two terms are slightly different
but still complementary to each other. The investigated
group of the patients assessed their quality of life as
medium and indicated that the disease had the highest
influence on the RP and RE. BP was also quite important.
Nevertheless, the patients assessed their PF, and VT as high
in comparison with other QoL domains. In the literature,
there is agreement that systemic lupus erythematosus
induces a lower quality of life in patients [15–21]. Differ-
ences in particular domains of SF-36 are mainly caused by
cultural, socio-economical, and clinical factors. Results
which reveal the impact of those factors on the patients’
quality of life, as well as particular domains measured in
SF-36, were presented elsewhere [22]. The factors taken
into consideration in this study were the level of education,
Fig. 3 Correlations between domains of SF-36 and clinical manifes-
tations of SLE. RE role emotional, UV photosensitivity, SF social
functioning, CNS neurological symptoms of SLE, MH mental health,
K renal manifestations of SLE
Fig. 2 Percentage distribution of satisfaction with life in SLE patients
(lLS1-lLS4 low life satisfaction, mLS5-mLS6 medium life satisfaction,
hLS7-hLS10 high life satisfaction). The most common answers in all
three divisions of satisfaction are marked in black
Table 2 Correlations between quality of life using SF-36 and
satisfaction with life using SWLS
SWLS vs ρ
a p
b
PF 0.43 <0.001
BP 0.37 =0.001
GH 0.42 <0.001
SF 0.51 <0.001
RP 0.31 =0.006
RE 0.67 <0.001
MH 0.57 <0.001
VT 0.44 <0.001
aSpearman’s rank correlation coefficient,
bStatistical significance
Table 3 Correlations between activity of SLE (using SLAM) and
quality of life (using SF-36)
Activity of SLE vs ρ
a p
b
PF −0.31 =0.02
BP −0.25 >0.05
GH −0.07 >0.05
SF −0.21 >0.05
RP −0.20 >0.05
RE −0.19 >0.05
MH −0.25 =0.05
VT −0.32 =0.03
aSpearman’s rank correlation coefficient
bStatistical significance
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whether the patient was the only person working in the
family. To summarise, we showed that worse socioeco-
nomic conditions were correlated with a higher satisfaction
with life.
There are not many reports in the literature on the
satisfaction with life of chronically ill patients. Moreover,
according to our knowledge, no studies on this subject have
been published in relation to patients with connective tissue
diseases, especially SLE. A Polish study carried out by
Juczyński et al. [14] apart from presenting the results of SL
assessed by the Satisfaction with Life Scale in patients with
selected chronic diseases (diabetes, stage renal disease
(ESRD), and status post myocardial infarction) also con-
tains the Polish norms.
Our results have revealed that the patients registered a
low satisfaction with life around twice as often as compared
with the general Polish population. They have a similar
relationship to the results achieved for quality of life, which
was further confirmed by statistically significant correla-
tions between QoL and SL. Therefore, it can be seen that
when quality of life increases, satisfaction is also higher.
This relationship provides evidence that satisfaction is a
part of quality of life. Results obtained by SLE patients are
similar to those of patients with ESRD as well as men after
myocardial infarction [14].
On the other hand, the presented differences indicate that
those two terms are probably separate. It seems that quality
of life is a wider notion that remains closely related not
only to the somatic state of the patient but also to other
factors, such as socioeconomic status and demographic
factors. It therefore contains elements which can have a
long-lasting impact on it. On the other hand, satisfaction
with life seems to be related to emotions, expectations or
even attitude towards some events, thus it describes the
state which is more variable. Obviously, it is also somehow
connected with other factors such as age, sex, education, or
social functioning. The patient might report a low quality of
life because of a chronic disease which leads to disability,
while satisfaction with life is high because the patient can
still work or is satisfied with his/her family life. It seems
that a strict and precise separation of these two terms is not
possible. The investigated group of patients consisted of
people who lived in good social conditions. They were
mainly working or they received a disability pension.
Although we have revealed that patients’ better living
conditions are connected with higher satisfaction with life
(unpublished results), this is the opposite of the relationship
between their living conditions and quality of life, in that
better living conditions correlate with lower QoL [22]. It
can confirm the hypothesis that both terms should be
measured separately, as they cover slightly different areas
of life.
Literature data indicates that even if symptoms of the
disease are not very intensive and activity of the disease is
rather low, they can have a huge influence on quality of life.
In the present research, correlations between photosensitiv-
ity and the RE, neurological symptoms of SLE and SF, as
well as renal symptoms and MH were found. For other
clinical manifestations of SLE and domains of SF-36, no
correlations were present. It should be emphasized that the
patients studied had a mild or moderate course of the
disease. There were no patients with a severe renal
involvement, or with advanced neurological symptoms.
Further research is definitely needed in this field, ideally
conducted among patients with a severe course of the
disease, to allow a more comprehensive assessment of the
quality of life, as well as satisfaction with life.
In the literature, there is no information on the
relationship between the clinical symptoms of the disease
and satisfaction with life among SLE patients. In our group,
only patients with a neurological manifestation of the
disease presented lower life satisfaction, and lower quality
of life, whereas no correlations between SL and renal
involvement or photosensitivity were found. This observa-
tion suggests that quality of life and satisfaction with life
are close terms.
The results of various studies differ as regards the
influence of SLE activity on patients’ quality of life [18, 21,
23–26], which might be due to using different activity
Table 4 Results of satisfaction with life in SLE patients depends on
activity of the disease
x
a Min Max SD
Satisfaction with life/active SLE 16.45 6.0 33.0 6.92
Satisfaction with life/inactive SLE 15.56 7.0 27.0 5.40
Min minimal values, Max maximal values, SD standard deviation
aMean values
Table 5 Correlations between damage index (DI) and quality of life
in SLE patients (using SF-36)
DI vs ρ
a p
b
PF −0.13 >0.05
BP −0.01 >0.05
GH 0.07 >0.05
SF −0.01 >0.05
RP −0.23 =0.04
RE −0.14 >0.05
MH −0.06 >0.05
VT −0.22 =0.04
aSpearman’s rank correlation coefficient
bStatistical significance
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clinical manifestation of the disease, and also socio-
economic and cultural factors. The present study has
indicated that when the disease activity was higher, the
patients reported a lower quality of life. However, similar
findings were not observed for satisfaction with life. This
suggests that QoL and SL may be assessed separately to
enable a full examination of the patient’s state.
Also, the damage index (DI) and its effect on quality of
life and satisfaction with life seem to play an important
role. We revealed that the damage to organs occurring
during the disease course resulted in lower RP and VT
although no similar correlation between DI, activity of the
disease or SL was found. This observation might to a
certain degree confirm some differences between quality of
life and satisfaction with life. Moreover, it also suggests
that a clinical state of the patient assessed by measuring the
disease activity and damage does not go together with SL,
but at the same time creates QoL. According to the
literature data [27], it seems that results of SF-36 do not
fluctuate over time together with an increase in disease
activity and damage index. However, it is not known
whether the same situation pertains to satisfaction with life.
We believe that a longitudinal design is needed. It is worth
underlining once more that only patients with an unad-
vanced course of the disease participated in the study,
which may well have had an influence on the final result.
Many authors have been interested in the problem of the
effect of the damage index on quality of life in SLE
patients. Results presented by them confirmed statistically
significant correlations between domains of SF-36 and DI
[15, 21, 24, 28–30]. It seems that not the numerical value of
DI but the localization of damage is most important for the
future of the patient. Some authors [26, 31] consider that
the damage index affects only a mental aspect of QoL: a
consequence of coping strategies. The presented results are
in opposition to the observations made by other authors
[16, 19, 24, 32] who did not find any correlations between
the damage index and the quality of life in SLE patients.
The results presented by Gilboe et al. are interesting [27].
They observed patients for 2 years and showed that their
quality of life as well as activity of the disease did not
change although the damage index was higher. The authors
underlined the lack of changes in quality of life, although
this may have been due to the patients becoming accus-
tomed to the disease, accepting it, and finding their own
way to deal with it.
The results presented in this study have proven that
systemic lupus erythematosus has a great influence on the
psyche of the patients and indicate that there is a huge need
to support them. However, a longitudinal study might show
the aforementioned correlations over time. It seems that
standard therapeutic management should consist of meas-
urements of quality of life, and also satisfaction with life,
together with a clinical assessment of the patient’s state as
well as activity of the disease, collectively with the damage
index Even if clinical symptoms of SLE are not very
noticeable to the doctor, they may be a problem for the
patient and they cannot be ignored. The awareness that
the disease has such a strong impact on a mental state of the
patient as well as attitude towards life may improve
compliance.
The study was completed by measuring satisfaction with
life. Our results reveal that there are differences between
quality of life and satisfaction with life but also underlined
t h ei m p o r t a n c eo fb o t ha s p e c t s .T h e r e f o r e ,i ti sr e a s o n a b l et o
continue research and undertake an effort to improve the
mental comfort of the patients. We do believe that further
investigations in this field are necessary, especially with a
group of patients with more severe signs and symptoms of
SLE. It will allow a more precise assessment of the effect of
the disease on both quality of life and satisfaction with life.
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